MA14.06 Nintedanib-Docetaxel in 2nd Line Treatment in No Squamous Non-Small Cell Lung Cancer Patients, Refractory to First Line Treatment (GFPC02-15)
Keyword(s):
2021 ◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2009 ◽
Vol 9
(4)
◽
pp. 425-435
◽
Keyword(s):
2010 ◽
Vol 67
(2)
◽
pp. 475-479
◽
Keyword(s):